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Summary To determine if ovarian cancer patients would be suitable for MAGE-peptide vaccine-based immunotherapy, the frequency of
expression of the MAGE-1-4 genes in ovarian tumours was assessed using reverse transcription polymerase chain reaction (RT-PCR) and
product verification with digoxigenin-labelled oligonucleotide probes specific for each MAGEgene. In addition, the frequency of expression of
more recently discovered tumour antigens (BAGE, GAGE -1, -2 and GAGE -3, -6) was established using RT-PCR and ethidium bromide
staining. In this study 1/16 normal ovarian tissue specimens and 11/25 benign lesions expressed MAGE-1. In non-malignant tissue there was
preferential expression of MAGE-1 in premenopausal women. A total of 15/27 malignant specimens expressed MAGE-1, including 10/14
serous cystadenocarcinomas. Expression of other tumour antigens was infrequent. The finding of MAGE-1 expression in both benign and
malignant tissue questions previous assumptions regarding the role of MAGE genes in carcinogenesis. In addition, preferential MAGE-1 gene
expression in non-malignant premenopausal tissue suggests that the MAGE genes may be involved in cellular proliferation as opposed to
carcinogenesis or possibly that MAGE gene expression is under cyclical hormonal control. Finally, this study indicates that serous
cystadenocarcinomas may be suitable tumours for MAGE-1 peptide immunotherapy.
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Ovarian cancer is the most common cancer of the female genital
tract in the developed world and in the UK is responsible for approx-
imately 6% of all female cancer deaths (Office of Population
Censuses and Surveys, 1993). The prognosis of women diagnosed
with this condition is generally poor with an overall 5-year survival
of only 30%. The survival is much greater for early ovarian cancer
(stage 1, 5 year-survival 79%; Petterson, 1990), and the develop-
ment of a screening test to detect early malignancy is seen as a
priority by many investigators. However, the natural history of this
disease is poorly understood and it may be that the disease does not
have the characteristics that make it suitable for screening (Hulka,
1988). If the tumour has spread by the time of diagnosis a surgical
cure is unobtainable. However, primary cytoreduction and interven-
tion cytoreduction are now accepted standards of care (Hacker et al,
1983; Van der Burg et al, 1995), and subsequent treatment is usually
in the form of chemotherapy. A large number of chemotherapeutic
agents has been shown to be active in epithelial ovarian carcinoma,
including alkylating agents, cytostatic antibiotics, platinum
compounds, taxanes and topoisomerase modifiers. The fact that so
many agents have a role in the management of this disease is self-
evidently a reflection that none is entirely efficacious or appropriate
for use in all circumstances. New treatment modalities are needed
before a significant improvement can be expected in the prognosis
of women diagnosed with this condition.
One such potential new therapy is antigen-specific immuno-
therapy with MAGE gene products. Since the discovery of the
MAGE-1 antigen (Van Der Bruggen et al, 1991) this area of
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research has progressed rapidly. The MAGE gene family comprises
a series of 12 closely related genes (De Plaen et al, 1994). Of these,
MAGE-J, -2, -3, -4, -6 and -12 have been shown to be expressed in a
variety of tumours of different histological type (Brasseur et al,
1992; Weynants et al, 1994; Inoue et al, 1995; Patard et al, 1995).
MAGE-] and MAGE-3 are targets for specific immunotherapy as
they encode peptide antigens that are presented in association with
HLA class 1 molecules and are recognized by cytoxic T lympho-
cytes (CTLs). Clinical trials have been initiated to evaluate the role
of these peptides as 'tumour vaccines', designed to break tolerance
that may exist to these antigens and potentiate CTL activity.
MAGE gene expression in malignant ovarian tumours has previ-
ously been described (Yamada et al, 1995). We now report our
own findings in malignant tumours and in addition describe
MAGE gene expression in a range of benign ovarian pathological
tissue. We also report the frequency of expression of other 'tumour
antigens' - BAGE, GAGE-I and -2 and GAGE-3 and -6 (Boel et
al, 1995, Van Den Eynde et al, 1995) - which may have a future
therapeutic role. Our findings indicate a potential for expanding
the MAGE peptide vaccine programme to include some forms of
ovarian tumours, while questioning previous assumptions
regarding the role of the MAGE gene family in carcinogenesis.
MATERIAL AND METHODS
Tissue sample collection
Tissue for this study was collected from women undergoing
surgical management of gynaecological conditions at Derby City
General Hospital, Derby, Jessop Hospital for Women, Sheffield,
and Northern General Hospital, Sheffield, UK. Samples were
collected at the time of surgical excision and snap frozen in the
vapour phase of liquid nitrogen. All tissue was subsequently stored
in liquid nitrogen until laboratory processing.
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Table 1 PCR amplification programmes
Temperature and duration
Gene Denaturation Annealing Extension Cycle number
MAGE-1 940C for 1 min 720C for 1 min 720C for 2 min 30
MAGE-2 940C for 1 min 670C for 2 min 720C for 2 min 34
MAGE-3 940C for 1 min 720C for 2 min 720C for 2 min 33
MAGE-4 940C for 1 min 680C for 2 min 720C for 2 min 30
BAGE 940C for 1 min 620C for 2 min 720C for 2 min 34
GAGE-1 -2 940C for 1 min 560C for 2 min 720C for 2 min 28
GAGE-3 -6 940C for 1 min 580C for 2 min 720C for 2 min 28
PBGD 940C for 1 min 590C for 0.5 min 720C for 2 min 33
RNA extraction and cDNA synthesis
Total RNA was isolated from the frozen tissues using the
RNAzol method according to the manufacturer's guidelines
(Biotecx, Houston, TX, USA). For cDNA synthesis, 2 ,ug of total
RNA was prepared in diethyl-pyrocarbonate-treated water to a
volume of 9.5 ,ul and mixed with 0.5 pA of oligo-(dT)1,2 8 at
0.5 ,ug tl-l (Pharmacia Biotech, St Albans, UK), 0.5 tl of
RNAguard at 31 600 units ml-1 (Pharmacia), 4.0 ,ul of 5 x first-
strand buffer (Life Technologies, Paisley, UK), 2.0 gl of 0.1 M
DTT, 2 pl of each dNTP at 10 mm, 1.0 gl of Superscript reverse
transcriptase at 200 U ,tl-' (Life Technologies) to a total volume
of 20 ,ul and incubated at room temperature for 10 min and then
44°C for 2 h. Following incubation the cDNA was diluted to
100 .tl with water and stored at -20°C.
PCR amplification
The integrity of the RNA was confirmed by performing PCR
amplification of the cDNA with primers for porphobilinogen
deaminase (PBGD) (Finke et al, 1993). The presence of cDNA for
MAGE- 1 -2 -3 and 4 was then determined by PCR amplification in
a 50-,tl reaction containing 5.0 gl of cDNA, 5 tl of 10 x PCR
buffer (Boehringer Mannheim UK, Lewes, UK), 0.1 utl of each
dNTP at 100 mm, 0.5 tl of each primer at 80 ztm (see below),
1.0 unit of Taq polymerase (Boehringer) and 38.4 pl of water. The
presence of cDNA for BAGE, GAGE- 1, -2 and GAGE-3, -6, was
determined by similar PCR amplification reactions - on these
occasions however using 38.1 pg of water and 1 unit of DNA poly-
merase (Primezyme, Biometra). The reaction mixtures were then
subjected to the appropriate PCR programmes as described in
Table 1.
Oligonucleotide primers for PCR amplification
The oligonucleotide primers used were specific for each gene. All
primers corresponded to sequences located in different exons in
order to prevent false positives caused by genomic DNA contami-
nating the RNA preparations. The primer sequences for MAGE-1,
-2, -3 and 4 are described in Patard et al (1995). The other primer
sequences used are described in Table 2.
Detection of PCR products
After amplification, PCR products were prepared with 50 ,ul of
chloroform and 12.5 ,l of bromophenol blue. The products were
Table 2 Sequences of oligonucleotide primers used for PCR
Gene Sequence
BAGE Sense TGG CTC GTC TCA CTC TGG
A/S CCT CCT ATT GCT CCT GTTG
GAGE 1/2 Sense GAC CAA GAC GCT ACG TAG
3/6 Sense GAC CAA GGC GCT ATG TAC
A/S CCA TCA GGA CCA TCT TCA
PBGDa Sense ATG TCT GGT AAC GGC AAT GCGG
A/S TGG TTC CCA CCA CAC TCT TCT CTG
a PBGD primers designed by K Mulcahy.
then size-fractionated in 2% agarose gels containing ethidium
bromide and visualized using UV irradiation.
Further verification of the specific nature of the MAGE PCR
products was obtained by probing with a digoxigenin-labelled
oligonucleotide probe specific for individual MAGE genes. In
brief, following size fractionation PCR products were Southern
blotted onto Hybond-N nylon membranes, subjected to digoxi-
genin-labelled oligonucleotides (see below), processed according
to manufacturer's guidelines with the digoxigenin luminescence
detection kit for nucleic acids (Boehringer Mannheim UK, Lewes,
UK) and exposed to reflection autoradiography film (Dupont).
Oligonucleotide probes for Southern blotting
The synthesis and sequences of the oligonucleotide probe for each
MAGE gene is described in Mulchahy et al (1996).
Control RNA samples
Control cDNA samples were included in each PCR amplification.
Melanoma cell line MZ2-MEL-30 expresses MAGE-I, -2 and -3,
BAGE, GAGE-I, -2 and GAGE-3, -6. RNA prepared from this cell
line was therefore used as a control for expression of these genes. The
sarcoma cell line LB23-SAR expresses MAGE-4, and RNA from this
cell line was used as a control for MAGE-4 gene expression.
The level of MAGE, BAGE and GAGE expression in each
sample was classified positive or negative. A positive result indi-
cates a level of expression equal or greater than 1% of that in the
reference cell line, i.e. MZ2-MEL-30 (MACE-I, -2, -3, BAGE,
GAGE-I, -2 and GAGE-3, -6) and LB23-SAR (MAGE-4). A nega-
tive result indicates a level of expression less than 1% of that in the
reference cell line.
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Table 3 Results overview: MAGE, BAGE and GAGE gene expression in ovarian tissue as determined by RT-PCR
Histology Number of MAGE- MAGE- MAGE- MAGE- BAGE GAGE-1, -2 GAGE -3, -6
specimens 1 2 3 4
Normal 16 1 0 1 0 0 0 0
Benign 25 11 1 0 0 0 0 0
Malignant 27 15 1 0 1 1 2 1
Metastases 6 2 0 0 0 0 0 0
RESULTS Lane 1 2 3 4 5 6 7
In this study a total of 74 ovarian tissue specimens were analysed for
expression of MACE-1, -2, -3, -4, BAGE, GAGE-i, -2 and GAGE-3,
CACE-3, -6 using RT-PCR amplification with oligonucleotide
primers specific for each gene and detection of PCR products as
detailed in the previous section. The 74 specimens comprised 16
normal ovaries, 25 benign ovarian lesions, 27 malignant ovarian
lesions and six metastatic lesions from ovarian carcinoma.
An overview of the expression of each gene in this study of
ovarian tissue is provided in Table 3. A total of 1/16 normal tissue
specimens expressed MAGE-I and another expressed MAGE-3.
A total of 11/25 (44%) benign pathological lesions expressed
MAGE-1 and one expressed MAGE-2. In total, 15/27 (56%) malig-
nant ovarian tissue specimens expressed MAGE-1, with other gene
expression in this group detailed in Table 3. Two out of six
metastatic lesions expressed MACE-I. There was no pattern of
quantitative differences in the level of MAGE-I gene expression
between the malignant and non-malignant ovarian tissue speci-
mens. Figure shows representative results. The normal ovary
specimen OV35 has a lower level of MAGE-I gene expression
than some of the other tissues studied. In this study there is infre-
quent expression of all MACE, BACE and GAGE genes tested in
ovarian tissue apart from MAGE-I expression in benign and
malignant pathological tissue.
A detailed breakdown of the histological type of non-malignant
lesions (normal and benign specimens) studied and the MAGE-1
gene expression in these lesions is shown in Table 4. It can be seen
that a variety of different lesions express MAGE-i, including
inclusion cysts, cystadenomas and endometrioid cysts.
In non-malignant ovarian tissue a relationship was shown
between the menopausal status of the women providing the spec-
imen and the frequency of MAGE-I expression. A total of 10/21
(48%) samples obtained from premenopausal women expressed
MAGE-1, whereas only 2/20 (10%) examples from post-
menopausal women expressed this gene. This association reached
statistical significance using a chi-squared test (P < 0.05). Note
only 3/16 normal specimens came from premenopausal women
and that one of these was MAGE- positive.
Of the malignant tissue specimens included in this study
serous cystadenocarcinomas (10/14), mucinous carcinomas (2/7)
and granulosa cell tumour (2/2) expressed MAGE-1 mRNA.
MAGE-1 expression was also found in 1/2 Krukenberg tumours
(breast primary) and 2/6 metastatic specimens. Expression
of MAGE-2, -3, -4, BAGE, GAGE-I, -2 and GAGE-3, -6 was
infrequent (see Table 5).
A total of 23 ovarian carcinomas of epithelial origin are
included in this study. There is preferential expression of the
MAGE-I gene in serous tumours (10/14, 71%), with relatively
infrequent expression in other tumours of epithelial origin (2/9,
22%). The association between serous histology and MAGE-I
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Figure 1 MAGE-1 gene expression in ovarian tissue as detected by RT-
PCR, agarose gel electrophoresis and product verification with digoxigenin-
labelled oligonucleotide probes. OV3, endometrioma; OV7, mucinous
cystadenoma, OVI 1, 32, serous carcinoma; OV34, granulosa cell tumour;
OV35, normal ovary. Lanes 8, 9 and 10, 1:1, 1:10 and 1:100 dilutions of the
control cell line MZ2-MEL-30
expression is statistically significant (chi-squared, P < 0.05). Close
analysis of MAGE-1 expression in serous cystadenocarcinomas
reveals a trend towards expression in early stage (6/6 stage I
lesions MAGE- I positive, 4/8 stage II, III and IV lesions MAGE- l
positive).
In malignant tissue specimens studied we found no relation-
ship between MACE gene expression and patient age,
menopausal status, preoperative CA125 and outcome (although
follow-up times were insufficient to conduct a full analysis of
this parameter).
DISCUSSION
Ovarian carcinoma has a poor overall prognosis, reflecting a
disease that is usually diagnosed at an advanced stage and the limi-
tations of current screening and treatment modalities. Much work
is in progress to develop screening programmes that may improve
survival by assisting with earlier diagnosis. Progress is also being
made in improving surgical techniques and efficiency and opti-
mizing post-operative chemotherapy regimens. In addition, new
chemotherapeutic agents are continually being introduced and
some offer potential for the future.
New treatment modalities may also contribute to the therapeutic
armamentarium for women diagnosed with this condition. One
area of research currently stimulating much interest is that of
tumour immunology and immunotherapy. The use of
immunotherapy in ovarian carcinoma is not new; however,
previous work has been limited in effectiveness (Berek et al,
1995). A new form of antigen-specific immunotherapy has been
suggested by the discovery of the MACE gene family and related
tumour antigens.
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Table 4 MAGE-1 expression in non-malignant ovarian lesions
Histology Number of MAGE-1
specimens positive
Normal 16 1
Inclusion cysts 5 3
Serous cystadenoma 4 2
Mucinous cystadenoma 3 1
Pseudomyxoma 1 0
Serous borderline 2 0
Mucinous borderline 1 0
Fibroma 3 3
Endometriosis 2 2
Dermoid 3 0
It has previously been reported that MAGE, BAGE and GACE
genes are expressed only in malignant tissue, with the exception of
the male germline cells within the testis and the placenta (De Plaen
et al, 1994; Takahashi et al. 1995). These findings are potentially
highly significant because the gene products may represent
tumour-specific targets for immunotherapy. It is known that
MAGE-1 and -3 are targets for specific immunotherapy as they
encode peptide antigens that are presented in association with
HLA class 1 molecules and are recognized by CTL.'MAGE-I is
expressed in association with HLA-AI and -CW 1601 (Traversari
et al. 1992; Van der Bruggen et al, 1994a), whereas MAGE-3 is
expressed in association with HLA-A I and HLA-A2.01 (Gaugler et
al, 1994; Van der Bruggen et al, 1994b). Pilot studies have
commenced to assess the value of MAGE- 1-A 1, MAGE-3-A I and
MAGE-3-A2 peptides as tumour vaccines in a number of tumour
types - including malignant melanoma - that have previously been
shown to express the MAGE genes. It is hoped that immunization
with these peptides will induce a CTL response resulting in
tumour regression. It is as yet too early to say whether this will
become established as an effective form of cancer therapy.
However initial reports suggest there is reason for optimism
(Marchand et al. 1995).
In this study we have analysed normal ovarian tissue and a wide
variety of benign and malignant ovarian pathological specimens
for expression of the MAGE, BAGE and GAGE gene families. Our
findings contribute significantly to the knowledge in this field of
study and have implications for MAGE peptide vaccine clinical
trials.
A total of 1/16 normal ovarian tissue specimens analysed
expressed MAGE-I and 1/16 expressed MAGE-3. The MAGE-1-
positive normal ovary was the contralateral ovary to a MAGE-1-
positive stage Ia mucinous carcinoma. The MAGE-3 positive
normal ovary was the contralateral ovary to a stage Ilc serous
cystadenocarcinoma of unknown MAGE expression. Bilateral
ovarian carcinomas are known to occur and it is therefore possible
that the positivity for MAGE in these two samples reflected the
heterogeneity of the tissues analysed - with some tumour cells
being present in the RT-PCR samples but absent in the samples
examined by the pathologist.
Our findings in benign ovarian pathological specimens were
totally unexpected, with 11/25 lesions expressing MAGE-1
(Table 3). Of these benign lesions expressing MACE-I, inclusion
cysts, serous cystadenomas and mucinous cystadenomas are
considered putative precursor lesions, whereas fibromas are not
(Table 4). The natural history of ovarian carcinoma is poorly
understood; there is no general agreement on the most likely
premalignant lesion and it may be that the different histological
subtypes have a different natural history. The results of this study
do not show preferential MAGE gene expression in any candidate
precursor lesion over any other and so unfortunately do not impli-
cate any particular lesion.
One of the most significant observations from this study may be
the preferential MACE-I gene expression in non-malignant
ovarian tissue obtained from premenopausal women. This finding
has implications for current understanding of the role of the
MACE genes. Whereas trials have rapidly been developed to
exploit the therapeutic potential of MAGE gene expression, the
question as to the role of MAGE remains unanswered. The finding
of MAGE gene expression exclusively in malignant tissue implies
a role in carcinogenesis; however, none has yet been proven. A
direct relationship has been shown between MAGE gene expres-
sion and tumour progression (Brasseur et al, 1995); one might
therefore anticipate that MAGE gene expression is a relatively late
event in tumorigenesis and is implicated in tumour progression.
However, no other evidence has been presented to support this
hypothesis. Indeed it is open to question whether the MAGE genes
have a specific role or whether their expression in malignant tissue
is simply a consequence of the demethylation process that occurs
in many cancers. A number of authors have shown that MACE
gene expression can be up-regulated by the demethylating agent
5-Aza-2'-deoxycytidine (Weber et al, 1994; De-Smet et al, 1996;
Mori et al, 1996; Shichijo et al, 1996). The study of MAGE-1
protein expression with anti-MAGE- 1 monoclonal antibodies
could provide further information as to the role of MAGE genes.
However, at present there are no reliable commercially available
antibodies.
The finding of preferential MACE-1 expression in non-malig-
nant tissue has two possible explanations. Firstly the possibility
must be raised that MAGE- I expression is under cyclical hormonal
control. However, there is no suggestion that tumours previously
shown to express MAGE-I are under such hormonal control and
therefore this explanation would seem unlikely. A more acceptable
explanation may be that MAGE-I expression occurs in the ovary
Table 5 MAGE, BAGE and GAGE gene expression in malignant ovarian lesions as determined by RT-PCR
Histology Number of MAGE- MAGE- MAGE- MAGE- BAGE GAGE-1, -2 GAGE -3, -6
specimens 1 2 3 4
Serous 14 10 0 0 1 0 1 0
Mucinous 7 2 1 0 0 0 1 1
Endometrioid 2 0 0 0 0 0 0 0
Granulosa cell 2 2 0 0 0 0 0 0
Ovarian secondary 2 1 0 0 0 0 0 0
Metastases 6 2 0 0 0 0 0 0
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during the cyclical proliferation required for ovulation and repair,
but not during the period of ovarian quiescence that occurs at the
climacteric. This of course suggests that MAGE-I gene expression
does not play a role in carcinogenesis at all, rather in cellular
proliferation.
Our findings in malignant ovarian tissue may also be highly
relevant. Serous cystadenocarcinomas are the largest histological
class of ovarian cancer and it is in this tumour category that we
have shown preferential expression of MAGE-1. In addition, we
report that the frequency of expression in this tumour type is
greater in early-stage lesions. The finding of preferential expres-
sion in this tumour type is supported by other investigators
(Yamada et al, 1995). However Yamada et al reported more
frequent expression in later stage lesions. The discrepancy
between these reports is probably a reflection of the small number
of primary serous cystadenocarcinomas analysed in each series - a
total of 14 lesions in this report and 13 in the series reported by
Yamada. Another report shows higher frequency of BAGE and
GAGE expression in ovarian tumours (Russo et al, 1996), although
direct comparison with the results presented in this paper is not
straightforward and the disparity is quite possibly due to method-
ological differences, e.g. increasing the number of PCR cycles
could potentially increase the frequency of gene expression.
The finding of MAGE-1 gene expression in putative precursor
lesions and early-stage serous cystadenocarcinomas could be
interpreted as evidence that MAGE gene expression is an early as
opposed to late event in ovarian tumour carcinogenesis. This study
shows preferential MAGE-I gene expression in ovarian serous
cystadenocarcinomas. There is therefore potential to include this
tumour type in future MAGE-I vaccine trials. In addition we have
shown MAGE-I gene expression in a variety of non-malignant
ovarian lesions - preferential expression occurring in those lesions
obtained from premenopausal women. This finding questions
previous assumptions regarding the role of the MAGE gene family
in carcinogenesis and contributes to the growing body of knowl-
edge concerning the natural history of ovarian carcinoma.
ACKNOWLEDGEMENTS
The authors would like to thank Professor BW Hancock, Dr A
Blackett, Miss VA Brown, Ms S Crockett, Mrs L Hubbold, Mr
DAN Johnson, Mr J Monaghan, Dr K Mulcahy, Mr MEL
Paterson, Mr IV Scott, Professor F Sharp, Professor M Wells and
the theatre and nursing staff at Derby City General Hospital and
Jessop Hospital for Women for their invaluable assistance in the
conduct of this study.
REFERENCES
Berek JS and Martinez-Maza 0 (1995) Immunology and immunotherapy of ovarian
cancer. In Epitrlelioil Cotncer of the Ororv, Lawton FG, Neijt JP and Swenerton
KD (eds) pp. 220-247. BMJ Publishing Group: London
Boel P. Wildmann C. Sensi ML. Brasseur R, Renauld JC. Coulie P. Boon T, Van Der
Bruggen P (1995) BAGE: a new gene encoding an antigen recognised on
human melanomas by cytolytic T lymphocytes. Ihnrni,iti 2: 167-175
Brasseur F. Marchand M. Vanwijck R, Herin M, Lethe B, Chomez P and Boon T
( 1992) Human gene MAGE- I, which codes for a tumor-rejection antigen, is
expressed by sonme breast tumors. Itt J CoIicer 52: 839-841
nrasseur F. Rimoldi D. Lienard D. Lethe n. Carrel S. Arienti F. Suier L. Vanwijck R.
nourlond A. Humblet Y, Vacca A. Conese M. Lahaye T, Degiovanni G,
Deraemaecker R. neauduin M, Sastre X. Salamon E. Dreno n, Jager B, Knuth
A. Chevreau C. Suciu S. Lachapelle J-M, Pouillart P. Parmiani G. Lejeune F.
British Journal of Cancer (1998) 78(6), 816-821
Cerottini J-C. Boon T and Marchand M (1995) Expression of MAGE genes in
primary and metastatic cutaneous melanoma. Itot J Canicer 63: 375-380
De Plaen E, Arden K, Traversari C. Gaforio JJ, Szikora J-P. De Smet C, Brasseur F,
Van Der Bruggen P. Lethe B. Lurquin C, Brasseur R, Chomez P, de Backer 0,
Cavenee W and Boon T ( 1994) Structure, chromosomal localization, and
expression of 12 genes of the MAGE family. Iomnunogenetics 40: 360-369
De-Smet C. De-Backer 0. Faraoni 1. Lurquin C, Brasseur F and Boon T ( 1996) The
activation of human gene MAGE- I in tumour cells is correlated with genome-
wide demethylation. Proc Natil Acad Sci USA 93(14) 7149-7153
Finke J. Fritzen R. Ternes P. Lange W and Dolken G (1993) An improved strategy
and a useful housekeeping gene for RNA analysis from formalin-fixed,
paraffin-embedded tissues by PCR. BioTechnziques 14: 448-453
Gaugler B, Van Den Eynde B, Van Der Bruggen P, Romero P. Gaforio JJ. De Plaen
E, Lethe B, Brasseur F and Boon T (1994) Human gene MAGE-3 codes for an
antigen recognised on a melanomna by autologous cytolytic T lymphocytes.
J Esp Med 179: 921-930
Hacker NF. Berek JS. Lagasse LD. Nieberg RK and Elashoff RM (1983) Primary
cytoreductive surgery for epithelial ovarian cancer. Obstet Gv,naecol 61:
413-420
Hulka B (1988) Cancer screening: degrees of proof and practical application. Canzlcer
62: 1776-1780
Inoue H. Li J, Honda M. Nakashima H. Shibuta K. Arinaga S, Ueo H. Mori M and
Akiyoshi T (I1995) MAGE-1 mRNA expression in gastric carcinoma. Iiit J
Cancer (Pred Oncol) 64: 76-77
Marchand M. Weynants P, Rankin E, Arienti F. Belli F, Parmiani G. Cascinelli N.
Bourlond A, Vanwijck R, Humblet Y, Canon JL. Laurent C, Naeyaert JM.
Plagne R, Deramaeker R, Knuth A, Jaeger E, Brasseur F, Herman J, Coulie PG
and Boon T (1995) Tumor regression responses in melanoma patients treated
with a peptide encode by gene MAGE-3. Int J Catnc er 63: 883-885
Mori M, Inoue H, Mimori K, Shibuta K, Baba K, Nakashima H, Haraguchi M, Tsuji
K, Ueo H, Barnard GF and Akiyoshi T (1996) Expression of MAGE genes in
human colorectal carcinoma. Anntz Suig 224(2): 183-188
Mulchahy KA, Rimoldi D, Brasseur F, Rodgers S. Lienard D, Marchand M. Rennie
IG, Murray AK, McIntyre CA. Platts KE, Leyvraz S, Boon T and Rees RC
( 1996) Infrequent expression of the MAGE gene family in uveal melanomas.
IntlJ Cancer 66: 738-742
Office of Population Censuses and Surveys ( 1993) Mortality statistics: cause
(England and Wales) 1991. OPCS series DHZ, No. 18. London: HMSO
Patard J-J, Brasseur F, Gil-Diez S. Radvanyi F, Marchand M, Francois P, Abi-Aad A,
Van Cangh P. Abbou CC. Chopin D and Boon T (1995) Expression of MAGE
genes in transitional-cell carcinomas of the urinary bladder. Inlt J Cancer (Pred
Oncol) 64: 60-64
Petterson F (ed.) ( 1990) Annual report on the results of treatmnent in gynaecological
cancer. Imit J Gvnaecol Obstet 44: 1776-1780
Russo V, Dalerba P, Ricci A, Bonazzi C, Leone BE, Mangioni C, Allavena P,
Bordignon C and Traversari C (1996) MAGE. BAGE and GAGE genes
expression in fresh epithelial ovarian carcinomas. hit J Cantce- 67: 457-460
Schichijo S, Yamada A, Sagawa K, Iwamoto 0, Sakata M, Nagai K and Itoh K
(1996) Induction of MAGE genes in lymphoid cells by the demethylating agent
5-aza-2'-deoxycytidine. Jpn J Canicer Res 87(7): 751-756
Takahashi K, Shichijo S, Noguchi M, Hirohata M and Itoh K (1995) Identification of
MAGE- 1 and MAGE-4 proteins in spermatogomin and primary spermatocytes
of testis. Cancer Rex 55(16): 3478-3482
Traversari C. Van Der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De
Plaen E, Amar-Costesec A and Boon T (1992) A nonapeptide encoded by
human gene MAGE- I is recognised on HLA-A 1 by cytolytic T lymphocytes
directed against tumor antigen MZ2-E. J Exp Med 176: 1453-1457
Van Den Eynde B, Peeters 0, De-Backer 0, Gaugler B, Lucas S and Boon T
(1995) A new family of genes coding for an antigen recognised by
autologous cytolytic T lymphocytes on a human melanoma. J Exp Med
182(3): 689-698
Van Der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E. Van Den
Eynde B, Knuth A and Boon T (1991) A gene encoding an antigen
recognised by cytolytic T lymphocytes on a human melanoma. Science 254:
1643-1647
Van Der Bruggen P, Szikora J-P, Boel P, Wildmann C, Somville M, Sensi M and
Boon T (I 994a) Autologous cytolytic T lymphocytes recognise a MAGE- I
nonapeptide on melanomas expressing HLA-Cw(*) 1601. Elr J Iittntutinol 24:
2134-2140
Van Der Bruggen P. Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C,
Traversari C, Townsend A and Boon T (I 994b) A peptide encoded by human
gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes
that recognise tumour cells expressing MAGE-3. Eu(r I Imln1unol 24:
31)38-31)43
@) Cancer Research Campaign 1998
Tumour antigen expression in ovarian tissue 821
Van Der Burg MEL, Van Lent M, Buyse M. Kobierska A. Colombo N, Favalli G.
Lacave AJ. Nardi M. Penard J. Pecorelli S (1995) The effect of debulking
surgery after induction chemotherapy on the prognosis in advanced epithelial
ovarian cancer. An EORTC Gynaecological Cancer Co-operative Group study.
N Ensgl J Med 332(10): 629-634
Weber J. Salgaller M, Samid D, Johnson B. Herlyn M, Lassam N. Treisman J and
Rosenberg SA ( 1994) Expression of MAGE- I tumor antigen as up-regulated
C) Cancer Research Campaign 1998
by the demethylating agent 5-aza-21-deoxycytidine. Concer Re.s 54(7):
1766-1771
Weynants P. Lethe B, Brasseur F, Marchand M and Boon T ( 1994) Expression of
MAGE genes by non-small-cell lung carcinomas. hit J Cancer 56: 826-829
Yamada A. Kataoka A. Shichijo S. Kamura T. Imai Y, Nishida T and Itoh K (1995)
Expression of MAGE- I, MAGE-2, MAGE-3/-6 and MAGE-4a/4b genes in
ovarian tumours. lItt J Conzcer (Pred Onicol) 64: 388-393
British Journal of Cancer (1998) 78(6), 816-821
